Cellosaurus HEC-1 (CVCL_1274)

Cell line name HEC-1
Synonyms HEC1; Human Endometrial Cancer-1
Accession CVCL_1274
Resource Identification Initiative To cite this cell line use: HEC-1 (RRID:CVCL_1274)
Comments Part of: MD Anderson Cell Lines Project.
Microsatellite instability: Instable (MSI-high) (Sanger).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Disease Endometrial adenocarcinoma (NCIt: C7359)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_0293 (HEC-1-A); CVCL_S835 (HEC-1C); CVCL_S836 (HEC-1D)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; JCRB

Markers:
AmelogeninX
CSF1PO10,12
D13S31711,16 (Cosmic-CLP)
11 (JCRB)
D16S53911,12
D5S81811,13
D7S82011
TH016,7
TPOX11
vWA18
Web pages http://tcpaportal.org/mclp/
Publications

PubMed=4673779; DOI=10.1016/0002-9378(72)90861-7
Kuramoto H., Tamura S., Notake Y.
Establishment of a cell line of human endometrial adenocarcinoma in vitro.
Am. J. Obstet. Gynecol. 114:1012-1019(1972)

PubMed=4678779
Kuramoto H.
Studies of the growth and cytogenetic properties of human endometrial adenocarcinoma in culture and its development into an established line.
Acta Obstet. Gynaecol. Jpn. 19:47-58(1972)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=12227503; DOI=10.1111/j.1749-0774.2002.tb00103.x
Kurarmoto H., Hamano M., Imai M.
HEC-1 cells.
Hum. Cell 15:81-95(2002)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections JCRB; JCRB0042
Cell line databases/resources Cosmic-CLP; 907051
GDSC; 907051
LINCS_HMS; 50014
LINCS_LDP; LCL-1496
Biological sample resources BioSample; SAMN03472810
Chemistry resources ChEMBL-Cells; CHEMBL3308740
ChEMBL-Targets; CHEMBL1075462
Gene expression databases GEO; GSM827285
GEO; GSM1669873
Polymorphism and mutation databases Cosmic; 907051